Video

Dr. Sonpavde on the Need for Phase 3 Data With Pembrolizumab or Atezolizumab in Bladder Cancer

Guru P. Sonpavde, MD, discusses the need for phase 3 data evaluating frontline pembrolizumab or atezolizumab in bladder cancer.

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the need for phase 3 data evaluating frontline pembrolizumab (Keytruda) or atezolizumab (Tecentriq) in bladder cancer.

​In 2017, the FDA granted single-agent pembrolizumab and atezolizumab accelerated approvals for the frontline treatment of patients with locally advanced or metastatic bladder cancer who are ineligible for cisplatin-containing chemotherapy. The approvals were based off findings from the phase 2 KEYNOTE-052 (pembrolizumab) and IMvigor210 (atezolizumab) trials.

The agents appear feasible in ​patients with PD-L1–high disease, says Sonpavde. However, phase 3 clinical trials are needed to determine whether the agents are superior to the switch maintenance regimen of gemcitabine/platinum followed by avelumab (Bavencio) maintenance, says Sonpavde.

​The switch maintenance approach is backed by positive phase 3 data from the JAVELIN Bladder 100 trial, concludes Sonpavde.

Related Videos
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center